BioCryst Pharmaceuticals (NASDAQ:BCRX) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research note published on Tuesday,Benzinga reports. HC Wainwright currently has a $30.00 target price on the biotechnology company’s stock.

A number of other analysts also recently commented on BCRX. Evercore ISI boosted their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Needham & Company LLC restated a “buy” rating and issued a $15.00 price target on shares of BioCryst Pharmaceuticals in a report on Thursday, April 10th. JMP Securities reaffirmed a “market outperform” rating and set a $18.00 price objective on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Cantor Fitzgerald started coverage on BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They issued an “overweight” rating and a $20.00 target price on the stock. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $11.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Friday, April 11th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $16.22.

BioCryst Pharmaceuticals Trading Down 6.9 %

Shares of BCRX stock opened at $10.27 on Tuesday. The stock has a 50 day simple moving average of $7.78 and a 200-day simple moving average of $7.84. The company has a market cap of $2.15 billion, a price-to-earnings ratio of -16.84 and a beta of 1.08. BioCryst Pharmaceuticals has a 12-month low of $5.04 and a 12-month high of $11.11.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, May 5th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.27. The business had revenue of $145.53 million during the quarter, compared to analysts’ expectations of $126.83 million. During the same quarter in the previous year, the company posted ($0.17) EPS. The company’s revenue was up 56.8% compared to the same quarter last year. On average, equities analysts forecast that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in BioCryst Pharmaceuticals by 7.8% in the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock valued at $164,616,000 after buying an additional 1,583,826 shares during the last quarter. Eversept Partners LP grew its stake in BioCryst Pharmaceuticals by 269.9% during the 4th quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company’s stock valued at $14,892,000 after purchasing an additional 1,444,907 shares in the last quarter. Hillsdale Investment Management Inc. increased its holdings in BioCryst Pharmaceuticals by 65,213.3% during the 4th quarter. Hillsdale Investment Management Inc. now owns 542,100 shares of the biotechnology company’s stock worth $4,077,000 after purchasing an additional 541,270 shares during the last quarter. Balyasny Asset Management L.P. acquired a new position in shares of BioCryst Pharmaceuticals in the 4th quarter valued at approximately $3,983,000. Finally, Norges Bank purchased a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at approximately $3,947,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.